How the 340B Program Transforms Access to Vital Diabetes Medications
A New Groundbreaking Study Reveals Real-Life Impact, Cost Savings, and Barriers Faced by Underserved Diabetes Patients in Safety-Net Clinics The federal 340B Drug Pricing Program provides discounted drug prices to safety-net entities, enabling them to serve more vulnerable patients. This program has become indispensable with the escalating costs of medications, including high-cost injectable diabetes…
